Stem Cell Therapy for Female Fertility, Ovarian Aging & Menopause

Female fertility does not decline suddenly at menopause. It changes progressively as the ovaries age, often beginning years before menstrual cycles stop.

During this transition, women may experience reduced ovarian reserve, poorer response to IVF stimulation, irregular cycles and eventually perimenopause, followed by menopause and postmenopause.

For women who still wish to conceive—particularly those experiencing unusually early loss of ovarian function—this decline can create significant reproductive challenges.

Stem cell therapy for female fertility is one of the regenerative approaches being investigated and clinically developed to support ovarian tissue, cellular signaling and the ovarian microenvironment.

Interest has become especially strong in women with:

• Diminished ovarian reserve
• Poor ovarian response
• Premature ovarian insufficiency
• Early menopause
• Perimenopausal ovarian decline
• Previous ovarian damage
• Reduced ovarian function following chemotherapy or other medical treatment

The objective is not simply to change a laboratory value such as AMH. Regenerative fertility medicine looks more broadly at whether biological activity within ovarian tissue can be supported before or alongside assisted reproduction.

Fertility, Perimenopause and Ovarian Aging

Ovarian aging begins long before menopause.

Women are born with a finite population of ovarian follicles, and this pool progressively decreases throughout reproductive life.

At the same time, the ovarian environment itself changes.

Research into ovarian aging has identified changes involving:

• Mitochondrial function
• Oxidative stress
• DNA damage
• Blood supply
• Stromal tissue
• Inflammation
• Cellular communication
• Follicular-support cells

These changes contribute to declining fertility even before menstrual cycles become irregular.

A recent review describes ovarian aging as both a decline in follicle quantity and a progressive change in the ovarian microenvironment, which has become an important target for regenerative reproductive medicine.

What Happens During Perimenopause?

Perimenopause is the transitional period leading to menopause.

During this phase, ovarian activity becomes increasingly variable.

Women may notice:

• Changes in cycle length
• Missed periods
• Changes in menstrual flow
• Hot flushes
• Sleep disturbance
• Fluctuating estrogen levels
• Reduced fertility

However, ovarian activity has not necessarily stopped.

Ovulation may still occur intermittently, which means that pregnancy can still be biologically possible during perimenopause, although its probability is substantially lower than at younger reproductive ages.

For women wishing to conceive, this intermittent ovarian function is one reason timely evaluation is important.

AMH, Antral Follicle Count, FSH, menstrual history and ultrasound findings can help define whether useful ovarian activity remains.

Early Menopause and Premature Ovarian Insufficiency

Menopause normally occurs considerably later than the peak reproductive years.

When substantial ovarian dysfunction occurs before age 40, the condition is generally described as premature ovarian insufficiency (POI).

POI is sometimes referred to historically as premature menopause or premature ovarian failure, although ovarian insufficiency is more accurate because ovarian activity can occasionally occur intermittently.

Women with POI may experience:

• Irregular or absent menstruation
• Elevated FSH
• Low estrogen levels
• Reduced follicular activity
• Infertility
• Menopausal symptoms at a young age

POI has become one of the most important fields for stem-cell-based ovarian regeneration research.

A 2026 review concluded that mesenchymal stromal cells may influence ovarian tissue through paracrine signaling, angiogenesis, anti-apoptotic effects and regulation of pathways involved in follicular survival.

How Could Stem Cells Support Ovarian Function?

Most current regenerative research focuses on mesenchymal stromal/stem cells, often referred to as MSCs.

Their potential effect does not depend only on cells replacing damaged ovarian tissue.

A major mechanism appears to be the biological signals they produce.

These signals can influence surrounding ovarian cells through what is called paracrine signaling.

Potential effects being studied include:

• Supporting ovarian blood-vessel formation
• Reducing excessive cellular stress
• Influencing inflammation
• Supporting granulosa-cell survival
• Reducing apoptosis
• Improving communication within ovarian tissue
• Supporting follicular development

Recent reviews describe MSCs from adipose tissue, bone marrow, menstrual blood, endometrium and umbilical tissues as potential regenerative platforms for ovarian and endometrial dysfunction.

Stem Cell Therapy for Female Fertility in Women with Low Ovarian Reserve

Women with diminished ovarian reserve often still have ovarian activity, but fewer follicles are available for recruitment.

This is very different from assuming that the ovaries are completely inactive.

For selected patients, stem cell therapy for female fertility may therefore be considered as part of a broader regenerative strategy before another IVF attempt.

The therapeutic target is primarily the ovarian environment surrounding the remaining follicles.

Follow-up may include changes in:

• AMH
• FSH
• Antral Follicle Count
• Follicular development
• Menstrual activity
• Response to ovarian stimulation
• Number of oocytes retrieved

The clinically meaningful question is not simply whether one hormone value increases, but whether ovarian activity or IVF response changes in a way that creates additional reproductive opportunities.

Stem Cells and Perimenopausal Fertility

Perimenopause represents an especially interesting area for regenerative fertility because some ovarian activity often remains.

For a woman experiencing declining reserve but intermittent follicular development, the therapeutic aim may be to support the ovarian environment during a period when residual activity can still potentially be used.

This differs significantly from conventional treatment of menopausal symptoms.

Hormone therapy can replace estrogen and progesterone when medically appropriate, but it does not itself create new reproductive potential.

Regenerative approaches instead investigate whether ovarian tissue can be biologically supported when functional follicles remain.

The distinction between supporting residual ovarian activity and claiming to reverse reproductive aging is important.

Female age and chromosome biology continue to have major effects on the probability that an available oocyte will result in a healthy embryo.

What About Menopause?

Menopause is clinically recognized after 12 consecutive months without menstruation when there is no other cause.

At this point, spontaneous follicular activity has usually become very limited.

The reproductive situation is therefore different from diminished ovarian reserve or perimenopause.

Regenerative approaches targeting ovarian tissue have generated interest because experimental and early clinical studies have reported hormonal and follicular changes in some women with severe ovarian insufficiency.

However, the biological possibility of treatment depends greatly on whether residual functional ovarian tissue and recruitable follicles remain.

This makes accurate diagnosis particularly important.

A woman with POI at 35, a woman entering perimenopause at 44 and a woman several years into natural postmenopause at 55 represent very different biological situations.

They should not be grouped together under one concept of “ovarian rejuvenation.”

Stem Cell Therapy After Menopause

Postmenopause refers to the years following menopause.

Here, the potential objectives of regenerative ovarian research may extend beyond fertility.

The ovaries are also endocrine organs, and declining ovarian function affects estrogen production, bone health, cardiovascular health, metabolism and other systems.

Earlier ovarian-regeneration research has therefore explored whether cell-based approaches could eventually influence both reproductive and endocrine ovarian function.

From a fertility perspective, however, the presence or absence of remaining functional follicles becomes critical.

Regenerative medicine should therefore distinguish clearly between:

supporting ovarian tissue,
supporting endocrine function, and
creating realistic reproductive potential.

These are not necessarily the same clinical objective.

Stem Cells, Exosomes and the Ovarian Secretome

One important development in stem-cell research is the discovery that many regenerative effects may be produced by what stem cells release rather than by the cells themselves.

This mixture of secreted biological factors is called the secretome.

It includes:

• Growth factors
• Cytokines
• Proteins
• Extracellular vesicles
• Exosomes

This helps explain the close relationship between stem-cell and exosome therapy.

A 2026 review of POI describes MSC-derived exosomes and regulatory microRNAs as important mediators of ovarian angiogenesis, cellular survival and tissue repair.

Rather than representing unrelated therapies, stem cells and exosomes can therefore be viewed as different ways of influencing regenerative cellular communication.

Can Stem Cell Treatment Be Combined with IVF?

Yes, particularly when residual ovarian function is present.

A regenerative treatment can be performed before a subsequent IVF cycle, after which ovarian response can be reassessed.

This may be particularly relevant in women with:

• Poor response during previous IVF
• Low AMH
• Reduced Antral Follicle Count
• Early ovarian decline
• POI with intermittent activity
• Perimenopausal ovarian function

IVF then provides a practical way to evaluate whether useful follicular development can be obtained.

For women approaching later reproductive ages, timing remains important because regenerative treatment must be balanced against the continuing effect of age on oocyte chromosome quality.

Regenerative Fertility at Chania Fertility Unit

At Chania Fertility Unit, stem-cell-based approaches form part of a broader regenerative fertility program under the scientific direction of Dr Matthaios Fraidakis.

The emphasis is on individual reproductive biology rather than applying the same treatment to every patient.

A woman in her late 30s with low AMH, a 39-year-old with POI, a woman entering perimenopause and a postmenopausal woman all have different ovarian biology and different therapeutic objectives.

Evaluation can therefore include:

• Age
• Menstrual activity
• AMH and FSH
• Antral Follicle Count
• Ultrasound evidence of residual follicular activity
• Previous IVF response
• Previous pregnancy history
• Duration of ovarian insufficiency

This information helps determine whether a regenerative ovarian strategy can reasonably be integrated with IVF or another fertility plan.

Frequently Asked Questions

Can stem cells reverse menopause?

The more useful clinical question is whether residual ovarian activity remains and whether ovarian tissue can respond to regenerative stimulation. Perimenopause, POI, menopause and established postmenopause represent very different biological stages and should be evaluated separately.

Is premature ovarian insufficiency the same as menopause?

Not exactly. POI occurs before age 40 and ovarian activity can sometimes be intermittent. Natural menopause generally represents a later and more sustained loss of ovarian follicular function.

Can a woman become pregnant during perimenopause?

Yes. Ovulation can still occur during perimenopause, although fertility is substantially reduced because both follicle number and oocyte quality decline with age.

Can stem cell therapy help women with low AMH?

Low AMH is one setting in which regenerative ovarian strategies may be considered. The objective is to support ovarian tissue and residual follicular activity rather than simply increase an AMH result.

Are stem cells and exosomes the same treatment?

No. Stem cells are living cells capable of producing a wide variety of regenerative signals. Exosomes are extracellular vesicles released by cells and carry part of that biological information.

Can stem cell therapy be followed by IVF?

Yes. For women with residual ovarian activity, regenerative treatment may be planned before IVF and followed by reassessment of follicular development and ovarian response.

Stem Cell Therapy for Female Fertility: Looking Beyond Ovarian Reserve

Stem cell therapy for female fertility is most meaningful when ovarian aging is understood as a biological continuum.

Diminished ovarian reserve, perimenopause, premature ovarian insufficiency, menopause and postmenopause are related—but they are not identical conditions.

Each represents a different degree of follicular depletion and ovarian-function decline.

Regenerative medicine therefore needs to answer a more precise question than:

“Can ovarian aging be reversed?”

The more useful question is:

“What ovarian function remains, and can its biological environment be supported?”

Stem-cell research is increasingly focused on exactly this issue—using cellular and paracrine mechanisms to influence ovarian vascularization, inflammation, granulosa-cell survival, tissue repair and follicular activity. Recent 2025–2026 reviews describe this as one of the most active areas of regenerative reproductive research.

For women with early ovarian decline, POI or perimenopausal fertility concerns, this creates an increasingly personalized interface between regenerative medicine and assisted reproduction.